GB0127008D0 - Organic compounds - Google Patents

Organic compounds

Info

Publication number
GB0127008D0
GB0127008D0 GBGB0127008.1A GB0127008A GB0127008D0 GB 0127008 D0 GB0127008 D0 GB 0127008D0 GB 0127008 A GB0127008 A GB 0127008A GB 0127008 D0 GB0127008 D0 GB 0127008D0
Authority
GB
United Kingdom
Prior art keywords
organic compounds
compounds
organic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0127008.1A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to GBGB0127008.1A priority Critical patent/GB0127008D0/en
Publication of GB0127008D0 publication Critical patent/GB0127008D0/en
Priority to PE2002001085A priority patent/PE20030539A1/es
Priority to TW091132777A priority patent/TWI259085B/zh
Priority to ARP020104273A priority patent/AR037521A1/es
Priority to MYPI20024185A priority patent/MY136297A/en
Priority to CA002465680A priority patent/CA2465680A1/en
Priority to CNB028236912A priority patent/CN1269811C/zh
Priority to ES02787612T priority patent/ES2240830T3/es
Priority to PT02787612T priority patent/PT1446399E/pt
Priority to PCT/EP2002/012514 priority patent/WO2003040125A1/en
Priority to JP2003542171A priority patent/JP4199668B2/ja
Priority to DE60204044T priority patent/DE60204044T2/de
Priority to AT02787612T priority patent/ATE294787T1/de
Priority to HK05100405.4A priority patent/HK1068338B/en
Priority to BR0213990-1A priority patent/BR0213990A/pt
Priority to EP02787612A priority patent/EP1446399B1/en
Priority to US10/494,898 priority patent/US7271168B2/en
Priority to SI200230147T priority patent/SI1446399T1/xx
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • C07D311/82—Xanthenes
    • C07D311/90—Xanthenes with hydrocarbon radicals, substituted by amino radicals, directly attached in position 9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/10—Dibenzothiopyrans; Hydrogenated dibenzothiopyrans
    • C07D335/12—Thioxanthenes
    • C07D335/20—Thioxanthenes with hydrocarbon radicals, substituted by amino radicals, directly attached in position 9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)
GBGB0127008.1A 2001-11-09 2001-11-09 Organic compounds Ceased GB0127008D0 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
GBGB0127008.1A GB0127008D0 (en) 2001-11-09 2001-11-09 Organic compounds
PE2002001085A PE20030539A1 (es) 2001-11-09 2002-11-07 Derivados de piperazina antagonistas de los receptores de somatostatina sst1
TW091132777A TWI259085B (en) 2001-11-09 2002-11-07 Piperazine derivatives having SST1 antagonistic activity
ARP020104273A AR037521A1 (es) 2001-11-09 2002-11-07 Derivados de piperazina que tienen actividad antagonista del sst1, un proceso para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento para el tratamiento de la depresion, ansiedad y padecimientos bipolares y una combinacion
SI200230147T SI1446399T1 (en) 2001-11-09 2002-11-08 Piperazine derivatives having sst1 antagonistic activity
PT02787612T PT1446399E (pt) 2001-11-09 2002-11-08 Derivados de piperazina tendo actividade antagonista de sst1
DE60204044T DE60204044T2 (de) 2001-11-09 2002-11-08 Piperazin derivate mit sst1 antagonistischer wirkung
CNB028236912A CN1269811C (zh) 2001-11-09 2002-11-08 具有sst1拮抗活性的哌嗪衍生物
ES02787612T ES2240830T3 (es) 2001-11-09 2002-11-08 Derivados de piperazina con actividad antagonista de sst1.
MYPI20024185A MY136297A (en) 2001-11-09 2002-11-08 Piperazine derivatives having sst1 antagonistic activity
PCT/EP2002/012514 WO2003040125A1 (en) 2001-11-09 2002-11-08 Piperazine derivatives having sst1 antagonistic activity
JP2003542171A JP4199668B2 (ja) 2001-11-09 2002-11-08 Ｓｓｔ１アンタゴニスト活性を有するピペラジン誘導体
CA002465680A CA2465680A1 (en) 2001-11-09 2002-11-08 Piperazine derivatives having sst1 antagonistic activity
AT02787612T ATE294787T1 (de) 2001-11-09 2002-11-08 Piperazin derivate mit sst1 antagonistischer wirkung
HK05100405.4A HK1068338B (en) 2001-11-09 2002-11-08 Piperazine derivatives having sst1 antagonistic activity
BR0213990-1A BR0213990A (pt) 2001-11-09 2002-11-08 Derivados de piperazina tendo atividade antagonìstica de sst1
EP02787612A EP1446399B1 (en) 2001-11-09 2002-11-08 Piperazine derivatives having sst1 antagonistic activity
US10/494,898 US7271168B2 (en) 2001-11-09 2002-11-08 Piperazine derivatives having SST1 antagonistic activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0127008.1A GB0127008D0 (en) 2001-11-09 2001-11-09 Organic compounds

Publications (1)

Publication Number Publication Date
GB0127008D0 true GB0127008D0 (en) 2002-01-02

Family

ID=9925528

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0127008.1A Ceased GB0127008D0 (en) 2001-11-09 2001-11-09 Organic compounds

Country Status (16)

Country Link
US (1) US7271168B2 (enExample)
EP (1) EP1446399B1 (enExample)
JP (1) JP4199668B2 (enExample)
CN (1) CN1269811C (enExample)
AR (1) AR037521A1 (enExample)
AT (1) ATE294787T1 (enExample)
BR (1) BR0213990A (enExample)
CA (1) CA2465680A1 (enExample)
DE (1) DE60204044T2 (enExample)
ES (1) ES2240830T3 (enExample)
GB (1) GB0127008D0 (enExample)
MY (1) MY136297A (enExample)
PE (1) PE20030539A1 (enExample)
PT (1) PT1446399E (enExample)
TW (1) TWI259085B (enExample)
WO (1) WO2003040125A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7390813B1 (en) 2001-12-21 2008-06-24 Xenon Pharmaceuticals Inc. Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
CN101083986A (zh) 2004-09-20 2007-12-05 泽农医药公司 双环杂环衍生物及其作为硬脂酰CoA去饱和酶(SCD)抑制剂的用途
US7951805B2 (en) 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
CA2580856A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
EP2289510A1 (en) 2004-09-20 2011-03-02 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
EP2316458A1 (en) 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
EP1804799B1 (en) 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
EP1799667B1 (en) 2004-09-20 2013-03-20 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
US7767677B2 (en) 2004-09-20 2010-08-03 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
EP2029138A1 (en) 2005-06-03 2009-03-04 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
GB0514615D0 (en) 2005-07-15 2005-08-24 Novartis Ag Organic compounds
HUE026815T2 (en) 2008-11-19 2016-07-28 Forum Pharmaceuticals Inc Treatment of Cognitive Disorders with (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
TWI519532B (zh) 2010-05-17 2016-02-01 艾維沃製藥公司 （Ｒ）－７－氯－Ｎ－（啶－３－基）苯並［b］噻吩－２－羧醯胺鹽酸鹽單水合物之結晶形體
RU2017136693A (ru) 2012-05-08 2019-02-08 Форум Фармасьютикалз, Инк. Способы поддержания, лечения или улучшения когнитивной функции

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5495047A (en) 1991-07-10 1996-02-27 Merck, Sharp & Dohme (Ltd.) Fused tricyclic compounds, pharmaceutical compositions containing them and their use in therapy

Also Published As

Publication number Publication date
PE20030539A1 (es) 2003-08-13
TW200300088A (en) 2003-05-16
JP4199668B2 (ja) 2008-12-17
JP2005516898A (ja) 2005-06-09
US20060079527A1 (en) 2006-04-13
EP1446399A1 (en) 2004-08-18
ES2240830T3 (es) 2005-10-16
EP1446399B1 (en) 2005-05-04
DE60204044T2 (de) 2006-01-19
WO2003040125A1 (en) 2003-05-15
DE60204044D1 (de) 2005-06-09
MY136297A (en) 2008-09-30
TWI259085B (en) 2006-08-01
CN1269811C (zh) 2006-08-16
AR037521A1 (es) 2004-11-17
PT1446399E (pt) 2005-09-30
HK1068338A1 (en) 2005-04-29
CA2465680A1 (en) 2003-05-15
ATE294787T1 (de) 2005-05-15
BR0213990A (pt) 2004-08-31
CN1596251A (zh) 2005-03-16
US7271168B2 (en) 2007-09-18

Similar Documents

Publication Publication Date Title
GB0108876D0 (en) Organic Compounds
GB0103389D0 (en) Organic compounds
GB0108606D0 (en) Organic compounds
GB0108337D0 (en) Organic compounds
GB0103303D0 (en) Organic compounds
GB0108087D0 (en) Organic compounds
GB0107368D0 (en) Organic compounds
GB0103258D0 (en) Organic compounds
GB0101598D0 (en) Organic compounds
GB0107365D0 (en) Organic compounds
GB0102841D0 (en) Organic compounds
GB0107506D0 (en) Organic compounds
GB0102090D0 (en) Organic compounds
GB0108095D0 (en) Organic compounds
GB0108352D0 (en) Organic compounds
GB0106652D0 (en) Organic compounds
GB0108101D0 (en) Organic compounds
GB0108089D0 (en) Organic compounds
GB0102948D0 (en) Organic compounds
GB0101993D0 (en) Organic compounds
GB0108093D0 (en) Organic compounds
GB0107507D0 (en) Organic compounds
GB0107508D0 (en) Organic compounds
GB0103047D0 (en) Organic Compounds
GB0106030D0 (en) Organic compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)